ASH 2022 | Update on a Phase I/II study of ziftomenib in patients with R/R AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some updates from the Phase I/II KOMET-001 trial (NCT04067336), which is evaluating ziftomenib, a novel menin inhibitor, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with specific molecular subtypes, namely KMT2A and NPM1 mutation. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kura Oncology: Consultancy, Honoraria, Other: Advisory Board, Steering Committee, Speakers Bureau; Abbvie: Consultancy, Honoraria, Other: member of data monitoring committee ; Mana Therapeutics: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Other: Advisory Board; Novartis: Consultancy, Honoraria, Other: Advisory Board; Kite Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Genentech: Consultancy; Takeda: Consultancy, Honoraria, Other: Advisory Board; Dava Oncology: Consultancy, Speakers Bureau; Rafael Pharmaceuticals: Other: Data Safety Monitoring Committee; Gilead: Consultancy, Honoraria, Other: Advisory Board; Daiichi Sankyo: Consultancy, Honoraria, Other: Advisory Board; PTC Therapeutics: Consultancy, Honoraria, Other: Advisory Board; Macrogenics: Consultancy; Stemline Therapeutics: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; Astellas: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; BMS/Celgene: Membership on an entity’s Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board.
